| MLPFX | MLPNX | MLPFX / MLPNX | |
| Total Expense Ratio | 1.44 | 3.49 | 41% |
| Annual Report Gross Expense Ratio | 1.45 | 3.49 | 42% |
| Fund Existence | 16 years | 14 years | - |
| Gain YTD | 20.326 | 22.114 | 92% |
| Front Load | 6% | N/A | - |
| Min. Initial Investment | 1000 | 1000 | 100% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 2.34B | 315M | 743% |
| Annual Yield % from dividends | 5.33 | 4.67 | 114% |
| Returns for 1 year | 23.23 | 24.19 | 96% |
| Returns for 3 years | 100.05 | 127.38 | 79% |
| Returns for 5 years | 151.83 | 217.38 | 70% |
| Returns for 10 years | 151.40 | 151.83 | 100% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BBP | 91.63 | 1.62 | +1.80% |
| Virtus LifeSci Biotech Products ETF | |||
| AVXC | 88.40 | 0.26 | +0.29% |
| Avantis Emerging Markets Ex-Chn Eq ETF | |||
| ABLD | 30.24 | -0.02 | -0.05% |
| Abacus FCF Real Assets Leaders ETF | |||
| XAPR | 37.65 | -0.04 | -0.12% |
| FT Vest US Eq Enh & Mod Buf ETF-Apr | |||
| CSQ | 20.47 | -0.05 | -0.24% |
| Calamos Strategic Total Return | |||